A Look At Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated Approval Plans

Simply Wall St.03-25 22:13

Beam Therapeutics (BEAM) shares are in focus after the company reported updated Phase 1/2 data for its AATD candidate BEAM-302, selected 60 mg as the preferred dose, and outlined plans for an ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622607711?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-25 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622607711","market":"hk","top_or_hot":-1,"title":"A Look At Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated Approval Plans","media":"Simply Wall St.","content":"<div>\n<p>Beam Therapeutics (BEAM) shares are in focus after the company reported updated Phase 1/2 data for its AATD candidate BEAM-302, selected 60 mg as the preferred dose, and outlined plans for an ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-positive-be\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated Approval Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated Approval Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-25 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-positive-be><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beam Therapeutics (BEAM) shares are in focus after the company reported updated Phase 1/2 data for its AATD candidate BEAM-302, selected 60 mg as the preferred dose, and outlined plans for an ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-positive-be\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-positive-be","article_id":"2622607711","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-positive-be","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622607711","pubTimestamp":1774448035,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Beam Therapeutics (BEAM) shares are in focus after the company reported updated Phase 1/2 data for its AATD candidate BEAM-302, selected 60 mg as the preferred dose, and outlined plans for an accelerated approval path.\nSee our latest analysis for Beam Therapeutics.\nDespite the BEAM-302 update, Beam Therapeutics’ shares have lost ground in the short term, with a 30 day share price return of 13.19% and a 90 day share price return of 14.89%. However, the 1 year total shareholder return remains...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BEAM":"Beam Therapeutics, Inc.","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4588":"碎股","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4535":"淡马锡持仓","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4611":"AI医疗"},"translate_title":"在积极的BEAM 302数据和加速批准计划后看看Beam Therapeutics(BEAM)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":1.5},"content_text":"Beam Therapeutics (BEAM) shares are in focus after the company reported updated Phase 1/2 data for its AATD candidate BEAM-302, selected 60 mg as the preferred dose, and outlined plans for an accelerated approval path. See our latest analysis for Beam Therapeutics. Despite the BEAM-302 update, Beam Therapeutics’ shares have lost ground in the short term, with a 30 day share price return of 13.19% and a 90 day share price return of 14.89%. However, the 1 year total shareholder return remains positive at 3.14%, which hints that recent enthusiasm has cooled after earlier gains. If this kind of clinical catalyst has your attention, it can be useful to see what else is moving in related areas using our screener for 36 healthcare AI stocks With shares giving up some recent gains and the company still loss making on US$139.7m of revenue, the key question is whether Beam is being overlooked or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 84% Undervalued With Beam Therapeutics last closing at $23.95 against a narrative fair value of $150, the gap between market price and thesis-driven valuation is wide and hard to ignore.  Beam represents \"Gene Editing 2.0\". Its base editing platform is a \"molecular pencil\", a precision instrument that chemically rewrites a single \"letter\" of the genetic code without cutting the DNA backbone. This approach offers a potentially superior safety and precision profile, designed to mitigate the core risks that plague its predecessors.  Read the complete narrative. Want to see why this narrative points to such a steep discount? The core assumptions rest on blockbuster potential for just two programs and meaningful balance sheet support. Curious how those ingredients combine into a triple digit fair value and what is left out of the model entirely? According to davidlsander, the focus is squarely on BEAM-101 and BEAM-302, with an rNPV framework that leans on program level probabilities of success, pricing power assumptions and a sizable cash contribution. The narrative does not assign value to several earlier assets or to the ESCAPE platform, yet still reaches a fair value that is many times the current share price, which helps explain why followers of this thesis see Beam as materially mispriced by the market. Result: Fair Value of $150 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear pressure points. These include any disappointment in upcoming BEAM-302 data, as well as potential delays and safety concerns across Beam’s broader base editing pipeline. Find out about the key risks to this Beam Therapeutics narrative. Another Way To Look At Valuation That $150 narrative fair value presents a very bullish picture, but the simple P/S check tells a different story. Beam trades at 17x sales, compared with a 10.6x industry average, a 15.5x peer average and a fair ratio of just 0.6x. This comparison points to meaningful valuation risk if sentiment cools. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:BEAM P/S Ratio as at Mar 2026Next Steps Seeing mixed signals across valuation, risks and rewards? Take a moment now to review the numbers yourself and decide where you stand on the 2 key rewards and 3 important warning signs Looking for more investment ideas? If you are weighing what to do next after Beam Therapeutics, do not stop here. Broader ideas can sharpen your watchlist and reveal opportunities others might ignore.  Spot potential bargains early by scanning companies that combine quality with attractive pricing using the 58 high quality undervalued stocks. Prioritize resilience and capital protection by filtering for companies with stronger finances through the 73 resilient stocks with low risk scores. Hunt for lesser known opportunities with solid fundamentals via the screener containing 25 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Beam Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622607711","isCrawlerRequest":true}